Filing Flows › Editas Medicine (EDIT) › Q2 2025
Editas Medicine (EDIT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Editas Medicine (EDIT) reported revenue of $3.6M for the second quarter 2025 (Q2 2025), +597% from a year earlier and -23% from the quarter before.
Editas Medicine, Q2 2025: revenue $3.6M (+598% year over year), net loss $53.2M, operating cash flow −$50.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.6M | -23% | +597% |
| Operating profit | −$51.5M | — | — |
| Net earnings | −$53.2M | — | — |
| Operating cash flow | −$50.2M | — | — |
What changed
Revenue was $3.6M in Q2 2025, up 597% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $51.5M, an operating margin of -1440.6%. Total costs fell 24% while revenue rose 597%. The quarter ended with a net loss of $53.2M, narrower than the previous quarter's $76.1M loss.
Operating cash flow was −$50.2M. Non-cash charges added back $1.8M of depreciation and $2.7M of share-based compensation.
Questions
What was Editas Medicine's revenue in the second quarter 2025?
Editas Medicine (EDIT) reported revenue of $3.6M for the second quarter 2025 (Q2 2025), +597% from a year earlier and -23% from the quarter before.
Source: Editas Medicine 10-Q on SEC EDGAR.